Virpax Pharmaceuticals Inc. is a biopharmaceutical company specializing in the development of non-opioid pain management treatments. Targeting the critical need for alternatives to opioid analgesics, Virpax focuses on creating innovative delivery systems that enhance the efficacy and convenience of pain relief medications. The company's pipeline includes various formulations aimed at addressing acute and chronic pain in both adults and children. These treatments are often based on advanced technology platforms designed to optimize delivery and absorption, offering potential improvements over traditional methods. Virpax Pharmaceuticals operates primarily within the healthcare sector, impacting industries such as pharmaceuticals and biotechnology. Its role in the financial market is significant, as it contributes to the ongoing efforts to tackle the opioid crisis by offering promising non-addictive pain management options. Listed on major stock exchanges, the company attracts attention from investors interested in healthcare innovations and emerging solutions in pain management.